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Medicine-related beliefs predict attribution of
symptoms toa shammedicine:Aprospective study
Rebecca K. Webster1* , John Weinman2 and G. James Rubin1
1Department of Psychological Medicine, Weston Education Centre, Institute of
Psychiatry, Psychology and Neuroscience, King’s College London, UK
2Institute of Pharmaceutical Science, King’s College London, UK
Objectives. To investigate a range of possible predictors of nocebo responses to
medicines.
Design. Prospective cohort study.
Methods. In total, 203 healthy adult volunteers completed measures concerning
demographics, psychological factors, medicine-related beliefs, baseline symptoms, and
symptom expectations before taking a sham pill, described as ‘a well-known tablet
available without prescription’ that was known to be associated with several side effects.
Associations between these measures and subsequent attribution of symptoms to the
tablet were assessed using a hurdle model consisting of a joint logistic and truncated
negative binomial regression.
Results. Men had an increased odds of attributing symptoms to the tablet OR = 1.52,
and older participants had decreased odds, OR = 0.97. Medicine-related beliefs were
important, with modern health worries, belief that medicines cause harm and perceived
sensitivity to medicines associated with increased odds of symptom attribution,
OR = 1.02, 1.10, 1.09, respectively. Trust in medicines and pharmaceutical companies
decreased the odds of symptom attribution, OR = 0.91, 0.88, respectively. The number
of symptoms at baseline and the expected likelihood of symptoms were associated with
an increased odds of attributing symptoms to the tablet, OR = 1.07, 1.06, respectively.
Anxiety, previous symptom experience, symptom expectations, and modern health
worries were also important in predicting the number of symptoms participants
attributed to the tablet.
Conclusion. It is hard to predict who is at risk of developing nocebo responses to
medicines from demographic or personality characteristics. Context-specific factors
such as beliefs about and trust in medicines, current symptoms and symptom
expectations are more useful as predictors. More work is needed to investigate this in
a patient sample.
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Statement of contribution
What is already known on this subject?
 Many patients report non-specific side effects to their medication which may arise through a
nocebo effect.
 Whether some people are particularly predisposed to experience nocebo effects remains unclear.
What does this study add?
 Demographic and personality characteristics are poor predictors of symptom attribution to a sham
medicine.
 Instead, context-specific factors that concern people’s beliefs surrounding medicines, their current
symptoms, and symptom expectations are more useful as predictors of symptom attribution.
Patients often experience symptoms that they attribute to theirmedication. However, not
all side effects are the result of the pharmacological action of a medication. Indeed, it has
been suggested that anywhere between 38% and 100% of apparent side effects are caused
by other factors (Mahr et al., 2017). The nocebo effect, defined as the experience of
unpleasant or noxious symptoms in response to an inert exposure (Kennedy, 1961), is
believed to explain many of these non-specific side effects (Barsky, Saintfort, Rogers, &
Borus, 2002). As such, the nocebo effect can also be operationalized as the non-specific
symptoms that occur after taking a medication which are attributed to the medication
(Faasse & Petrie, 2013).
A good example of this has been the recent controversy in the media over the muscle
symptoms that some patients experience to their statin medication. High rates of side
effects have been attributed to statins among primary care patients (Saxon&Eckel, 2016);
however, clinical trials of statins have found side effect rates to be roughly similar in both
patients allocated statins and those allocated a sham tablet (Collins et al., 2016; Tobert &
Newman, 2016) ‘Statin intolerance’ may therefore be wholly or partly mediated by a
nocebo effect, exacerbated by adverse media coverage (Horton, 2016). Similar effects
have been proposed for other surprisingly high rates of side effect reporting for
medications, such as for oseltamivir during the swine flu outbreak (Kitching, Roche,
Balasegaram, Heathcock, & Maguire, 2009) and ciprofloxacin for anthrax exposure
(Rubin & Dickmann, 2010; Stein et al., 2004).
Whether related to the pharmacological action of a medication or not, side effects can
reduce patient well-being and be a cause of patient non-adherence (Ammassari et al.,
2001;Kardas, Lewek,&Matyjaszczyk, 2013), bothofwhich can lead to a significant cost to
health services (National Institute For Health and Clinical Excellence, 2009). To reduce
the negative impact of side effects, it is important to understand more about their causes.
Previous research has suggested that expectations (Bingel et al., 2011; Hahn, 1997),
learning (Van den Bergh, Kempynck, van de Woestijne, Baeyens, & Eelen, 1995; Vogtle,
Barke, & Kroner-Herwig, 2013), and misattribution of coincidental symptoms (Petrie,
Moss-Morris, Grey, & Shaw, 2004; Petrie et al., 2005) may increase the risk of a nocebo
effect occurring. Whether some people are particularly predisposed to experiencing a
nocebo effect remains unclear. Several potential predisposing factors have been
suggested including gender (Liccardi et al., 2004), anxiety (Nevelsteen, Legros, &
Crasson, 2007), somatization (Szemerszky, Koteles, Lihi, & Bardos, 2010), somatosensory
amplification (Witth€oft & Rubin, 2013), low optimism (Geers, Helfer, Kosbab,Weiland, &
Landry, 2005), and baseline symptoms (de la Cruz, Hui, Parsons, & Bruera, 2010).
However, in a systematic review, Webster, Weinman, and Rubin (2016) highlighted
inconsistent findings with regard to the importance of these factors.
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Although dispositional predictors of nocebo effects are not consistent across the
literature, there is an important literature concerning peoples’ beliefs about medicines,
which have been consistently shown to influence not only peoples’ use of treatment but
also their reporting of side effects. Medicine-related beliefs include people’s beliefs about
the necessity, harm and use of medicines, their perceptions of their own sensitivity to
medicines, and their worries about the health effects of modern medicine. These can all
work to increase peoples’ expectations of side effects (Faasse & Petrie, 2013), one ofmain
mechanisms of nocebo effects (Webster et al., 2016). Medicine-related beliefs have
previously been shown to be associated with patients’ choice of medicine (e.g.,
complementary vs. conventional, or generic vs. branded) (Andersson Sundell & J€onsson,
2016; Figueiras et al., 2010; Petrie et al., 2001), their adherence to their medication
(Horne, Chapman, et al., 2013; Menckeberg et al., 2008; Phatak & Thomas, 2006), their
information seekingbehaviour (Faasse,Grey,Horne,&Petrie, 2015), symptomattribution
to a hypothetical medication (Heller, Chapman, & Horne, 2015), and side effect reporting
to medications and vaccinations (Nestoriuc, Orav, Liang, Horne, & Barsky, 2010; Petrie
et al., 2004; Rief et al., 2012). Given how prevalent these beliefs are, and the importance
they have for patients’ decisions and experiences inmedical settings, it would be useful to
evaluate the contribution of these factors in predicting nocebo responses.
Identifying associations between these variables and symptom attribution might
enable clinicians to improve their interactions with patients; the way they address
potential side effectswith their patients; and allow researchers to develop interventions to
target those most at risk of developing a nocebo effect.
As part of a randomized controlled trial testing the effect of patient information leaflet
(PIL) wording on symptom attribution, we tested whether the following potential
predictors were associated with the attribution of symptoms by healthy participants to a
sham medicine: (1) demographics, (2) anxiety, (3) optimism, (4) somatization, (5)
somatosensory amplification, (6) previous symptoms, (7) expected side effects, (8)
modern health worries, (9) beliefs about medicines, (10) perceived sensitivity to
medicines, and (11) trust in medicines and pharmaceutical companies.
Method
Design
This brief prospective cohort study formed part of a randomized controlled trial,
additional results for which have been reported elsewhere (Webster, Weinman & Rubin,
2018). It took place at the Wellcome Trust King’s Clinical Research Facility and was
approved by the King’s College London Psychiatry, Nursing and Midwifery Research
Ethics Subcommittee (PNM 14/15-62).
Participants
To be included in the study, participants had to be healthy, aged 18 or over, and fluent in
English. This was assessed through a screening questionnaire. Participants with a
condition currently causing symptoms such as a chronic or acute illness or those who
were pregnant or breast feeding were excluded to prevent any interference with
symptom reporting. To enhance the appearance of a genuine drug trial, participantswere
asked to list any allergies tomedicines and/or the inactive ingredients often found in them.
Examples of the potential inactive ingredients were given, and these covered all the
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ingredients included in our sham tablet. Participants who listed allergies to any of the
substances in our tablet were excluded. On the day of participation, participants who had
taken any pain killers within 4 hrs before taking part or who had been drinking alcohol
were rescheduled.
Sample size
The sample size calculation was based on identifying an effect on symptom attribution
from the intervention tested in our RCT, the results of which are reported elsewhere
(Webster et al., 2018). The associations tested here are therefore exploratory.
Measures
Demographics
Participants were asked their age, gender, ethnicity, highest level of education, and
employment status.
Psychological factors
The following measures were included at different phases of the study (see Figure 1).
The State Anxiety Inventory – short version (Marteau & Bekker, 1992) – was used to
assess levels of anxiety experienced at the time of measurement. This includes six items
which participants rated on a 4-point scale ranging from 1 ‘not at all’ to 4 ‘verymuch’. The
scores range from 6 to 24 with higher scores indicating greater anxiety.
The Somatosensory Amplification Scale (Barsky, Goodson, Lane, & Cleary, 1988) was
used to assess participants’ tendency to experience a somatic sensation as intense,
noxious, or disturbing. This 10-item scale measures the tendency to experience somatic
sensations as intense, noxious, anddisturbing. Participants rated thedegree towhicheach
statement is characteristic of them in general on a 5-point scale ranging from 1 to 5. The
scores range from 10 to 50 with higher scores indicating greater somatosensory
amplification.
The Patient Health Questionnaire Somatic Symptom Severity Scale (Kroenke, Spitzer,
& Williams, 2002) was used to assess somatization. This is a 15-item scale designed to
measure the prevalence of the most common bodily symptoms (e.g., headache, nausea)
experienced in the last 4 weeks. Participants rated each item on a 3-point scale ranging
from 0 ‘not bothered at all’ to 2 ‘bothered a lot’. The scores range from 0 to 30with higher
scores indicating greater somatization.
The Revised LifeOrientation Test (Scheier, Carver, & Bridges, 1994)was used to assess
dispositional optimism. This consists of six items (plus four filler items) which measures
where participants lie on the pessimism-optimism scale. Participants rated each item on a
5-point scale ranging from1 ‘strongly disagree’ to 5 ‘strongly agree’. The scores range from
6 to 30, with higher scores indicating greater optimism.
Symptoms
Participants’ symptom experience in the previous 24 hrs was assessed using a modified
version of the Generic Assessment of Side Effects Scale (GASE; Rief, Glombiewski, &
Barsky, 2009). The GASE is used to assess side effects in clinical trials and supports the
early detection of drug-induced adverse events. The side effects listed in our modified
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version were those commonly reported during a nocebo response (14 items) (Wells &
Kaptchuk, 2012) or which were already listed on the GASE, detectable within an hour of
taking the tablet, and not too serious (e.g., we removed ‘hair loss’ from the list) (nine
items). Participants rated each symptom on a 4-point scale ranging from 0 ‘not present’ to
3 ‘severe’. Scores range from 0 to 23 for the number of symptoms and 0 to 69 for the
severity of symptoms.
Figure 1. Study procedure.
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Symptom expectations were also assessed with a modified version of the GASE (Rief
et al., 2009) as used similarly by Nestoriuc et al. (2016). The side effects listed were the
same; however, in this case, participants were asked to state how likely they thought they
were to experience the symptom in the hour after taking the tablet. Each symptom was
rated on a 4-point scale ranging from 0 ‘not very likely’ to 3 ‘very likely’. Scores range from
0 to 69 with higher scores indicating greater expectations of symptoms.
Medicine-related beliefs
Participants’ general beliefs about medicines were assessed using the overuse and harm
general subscales of the beliefs about medicines questionnaire (BMQ) which has been
shown to be both reliable and valid (Horne, Weinman, & Hankins, 1999). This included
eight items (four relating to harm and four relating to overuse) which participants’
measured on a 5-point scale, ranging from 1 ‘strongly disagree’ to 5 ‘strongly agree’. The
scores range from4 to 20withhigher scores indicating greater perceived harmor overuse.
The Modern Health Worries Scale (Petrie et al., 2001) assessed the extent to which
people had worries or concerns about different aspects of modern life (e.g., over use of
antibiotics, pesticide spraying etc.). Participants rated each item on a 5-point scale,
ranging from 0 ‘no concern’ to 4 ‘extreme concern’. The scores range from 0 to 128 with
higher scores indication greater worries about modernity.
The Perceived Sensitivity to Medicines Scale (Horne, Faasse, et al., 2013) assessed the
extent to which people felt that they were sensitive to different aspects of medication.
The scale includes five items assessing the extent to which people felt that they were
sensitive to different aspects of medication rated on a 5-point scale ranging from 1
‘strongly disagree’ to 5 ‘strongly agree’. The scores range from 5 to 25 with higher scores
indicating greater perceived sensitivity.
Trust in medicine was assessed using three bespoke items created for this study
regarding how much participants trusted the current process in which medicines were
developed, tested and approved for use, rating each statement on a 5-point scale from 1
‘strongly disagree’ to 5 ‘strongly agree’. The scores range from 3 to 15 with higher scores
indicating greater trust inmedicine. Trust in pharmaceutical companieswas also assessed
using two bespoke items created for this study which concerned whether participants
believed pharmaceutical companies acted in patients’ best interests and if they are only
interested in making money (reverse scored). Participants rated each statement on a 5-
point scale from 1 ‘strongly disagree’ to 5 ‘strongly agree’. The scores ranged from 2 to 10
with higher scores indication greater trust in pharmaceutical companies.
Symptom reports
Participants’ symptom reports after taking the tablet were again assessed with our
modified version of the GASE (Rief et al., 2009). This time, however, participants rated
each symptom on a 4-point scale ranging from 0 ‘not present’ to 3 ‘severe’ andwere asked
whether any symptom they experienced was related to taking the tablet –’yes’ or ‘no’.
Guess at tablet identity
Participants were asked to give their best guess at what the tablet was and how confident
they were from 1 ‘not at all confident’ to 5 ‘extremely confident’ about their answer.
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Procedure
Participants were recruited between 1 December 2015 to 5 December 2016 through
adverts on university circular emails and posts on the widely used online classifieds and
community website, GumTree. Interested people were emailed an information sheet
and a screening questionnaire to complete. Before providing consent, potential
participants were told the study would assess the severity of short-term side effects to
a well-known tablet and that we would not tell them what the tablet was till after data
collection for the whole study was finished, in order not to bias their views about the
tablet. This procedure minimized the amount of deception required in this study and
was used in accordance with the principles of ‘authorized deception’ (Miller, Wendler,
& Swartzman, 2005).
The researcher let participants know whether they were eligible and arranged a time
for them to participate. On the day, participants booked in at the reception of the
clinical research facility and were led to a fully equipped testing room. Before starting,
the researcher double-checked the participants’ screening questionnaire and went
through the consent form. After providing consent, participants answered questions
about their demographic characteristics, recent symptoms, modern health worries,
tendency for somatosensory amplification, belief about medicines, somatization,
optimism, perceived sensitivity to medicines, and anxiety. As part of the RCT,
participants were randomized to receive one of two leaflets about the tablet. Both
contained information about the same potential side effects, but framed positively (e.g.,
‘90% of people will not be affected’) or negatively (e.g., ‘one in 10 people will be
affected’). See Supporting Information for a copy of the leaflets. After reading the leaflet,
participants completed questions about their anxiety and expectation of side effects.
They then took the tablet with water. The tablet was manufactured by Guy’s and St
Thomas Pharmacy and contained the inactive ingredients lactose, microcrystalline
cellulose, and magnesium stearate. It was round, white, and had a breakline through the
centre.
Over the next hour, participants completed a variety of vigilance and cognitive tasks to
enhance the appearance of a formal clinical trial – data from these tasks were discarded.
Participants then completed questions about their anxiety, symptom experience during
thepast hour, and trust inmedicine andpharmaceutical companies. Trust inmedicine and
pharmaceutical companies was assessed after participants had taken the tablet to prevent
any concerns about taking the tablet that answering these questions could cause. All
participants received £40 for taking part via shopping vouchers or bank transfer. After all
participants had been tested, participants were emailed a debrief explaining the aims of
the study and revealing the tablet was a sham (placebo). A summary of the procedure can
be been seen in Figure 1.
Analysis
Ourprimary outcomeswere (1)whether participants attributed oneormore symptoms to
the sham medicine and (2) the number of symptoms participants attributed to the sham
medicine.
To analyse these outcomes, we used a hurdle model (Hu, Pavlicova, & Nunes, 2011;
Ridout, Demetrio, & Hinde, 1998) fitted to the dependent variable of the number of
symptoms attributed to the tablet. This consists of a joint logistic and truncated negative
binomial regression, providing us with information on the odds of participants
attributing one or more symptoms to the tablet, but also allowing us to identify the
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effect of the predictors on the number of symptoms participants go on to attribute to
the tablet. This is a more powerful analysis to use as our data contained an excess
number of zeros than would be expected by a normal negative binomial regression. A
truncated negative binomial regression was favoured to a truncated Poisson regression
due to over-dispersion in the data. Single regressions for each predictor were conducted
while controlling for gender, age, ethnicity, employment status, highest level of
education, and condition participants were randomized to. These variables were
controlled for due to suggestions in the literature that they can influence nocebo
responses (Bavbek, Aydin, S€ozener, & Y€uksel, 2015; Hahn, 1997; Papadopoulos &
Mitsikostas, 2012).
As a post hoc analysis, we also carried out a multivariate analysis in which all variables
(including all predictor and control variables) were entered at the same time to see
whether any of the predictors had an effect on our primary outcomeswhile controlling for
all other variables.
Analyses were carried out using Stata 15 (StataCorp LLC, College Station, TX, USA).
Results
Participant characteristics
The final sample contained 65 men and 138 women, with most of the sample being of
White ethnicity (59.6%). The mean age of the sample was 27.15 years. The full baseline
characteristics of the sample are shown in Table 1. For a diagram of participant flow
through the study, see Figure 2.
Symptom attribution
Themean number of symptoms attributed to the tablet was 1.03 (SD = 1.49). Almost half
of the participants (n = 95, 46.8%) attributed one or more symptoms to the tablet. Of the
108whodidnot attribute symptoms to the tablet, 37 (34.3%) experiencedno symptoms at
all, and 71 (65.7%) experienced one or more symptoms but did not attribute them to the
tablet.
Table 1. Baseline characteristics of the sample
Variable Total sample (N = 203)
Age 27.15 (8.63)
Number of baseline symptoms 2.60 (2.70)
Severity of baseline symptoms 2.95 (3.29)
Baseline anxiety 9.60 (2.71)
Gender
Female 138 (68.0)
Ethnicity
White 121 (59.6)
Education
Higher education 132 (65.0)
Employment
Not working 125 (61.6)
Note. Data are Mean (SD), or n (%).
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Predictors
Table 2 shows the association between themeasures andwhether participants attributed
one or more symptoms to the tablet, and the number of symptoms they go onto attribute.
Demographics
Men had a 52% increase in the odds of attributing symptoms to the tablet compared to
women. Older participants were less likely to attribute symptoms, with each increase
of 1 year in age resulting in a 3% decrease in the odds of participants attributing
symptoms to the tablet. There was no association between ethnicity, employment
status or education level, and attributing symptoms to the tablet. There was no
association between any of the demographic variables measured and the number of
symptoms attributed to the tablet.
Psychological factors
There was no effect of anxiety, optimism, somatization, or somatosensory amplification
on the odds of symptom attribution. With regard to the number of symptoms attributed,
only anxiety scores after reading the PIL showed a significant effect with each increase in
anxiety score being associatedwith a 6% increase in the rate of symptoms attributed to the
tablet.
Symptoms
For baseline symptoms, each increase in the number of symptoms in the previous 24 hrs
was associated with a 7% increase in the odds of attributing symptoms to the tablet. There
206 randomized
259 booked in
317 eligible 
320 completed 
screening 
465 interested in the 
study
-141 did not complete the screening 
questionnaire
-3 found out from the ISRCTN website 
and potentially knew tablet was a sham
-1 realized they could not take part as 
they were pregnant 
-3 had a medical condition currently 
causing symptoms and were not eligible
-58 did not book a time to participate
-38 cancelled and did not reschedule
-13 did not attend
-2 taking part in another medical based 
study at the same time so we cancelled 
their booking 
203 included in 
analysis
-2 ‘pilot runs’ excluded from final
sample
-1 lost due to IT outage 
Figure 2. Participant flow through the study.
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Table 2. Predictors of attributing one or more symptoms to the sham medicine and the number of symptoms which are subsequently attributed
Variable
No (%) or
Mean (SD)
Symptom attribution Number of attributed symptoms
Unadjusted OR
(95% CI)
Adjusted ORa
(95% CI)
Unadjusted RR
(95% CI)
Adjusted RRa
(95% CI)
Demographics
Gender
Male 65 (32.0) 1.37 (0.94–1.99) 1.52 (1.02–2.25) 0.90 (0.71–1.16) 0.85 (0.66–1.09)
Female 138 (68.0) Reference Reference Reference Reference
Age 27.15 (8.63) 0.98 (0.96–1.00) 0.97 (0.95–0.99) 1.00 (0.99–1.02) 1.01 (0.99–1.02)
Ethnicity
Other 82 (40.4) 0.93 (0.66–1.32) 0.91 (0.63–1.31) 0.89 (0.70–1.14) 0.89 (0.69–1.13)
White 121 (59.6) Reference Reference Reference Reference
Employment
Working 78 (38.4) 0.97 (0.68–1.39) 1.16 (0.77–1.76) 1.11 (0.86–1.42) 1.16 (0.89–1.52)
Not working 125 (61.6) Reference Reference Reference Reference
Education
School qualifications 71 (35.0) 1.23 (0.85–1.76) 1.11 (0.76–1.63) 1.05 (0.83–1.35) 1.15 (0.88–1.49)
University degree 132 (65.0) Reference Reference Reference Reference
Experimental condition
Control leaflet 101 (49.8) 1.47 (1.04–2.08) 1.47 (1.03–2.10) 0.82 (0.64–1.01) 0.76 (0.60–0.97)
Positively framed
leaflet
102 (50.2) Reference Reference Reference Reference
Psychological factors
Anxiety before
leaflet
9.60 (2.71) 1.01 (0.94–1.07) 1.01 (0.95–1.08) 1.03 (0.99–1.08) 1.03 (0.98–1.08)
Anxiety after leaflet 9.57 (2.51) 1.04 (0.97–1.12) 1.06 (0.99–1.14) 1.06 (1.02–1.11) 1.06 (1.01–1.11)
Anxiety 1 hr after
taking tablet
9.14 (2.62) 1.04 (0.97–1.11) 1.05 (0.98–1.12) 1.03 (0.99–1.08) 1.03 (0.99–1.08)
Change in anxiety 0.46 (2.34) 1.04 (0.96–1.12) 1.04 (0.96–1.12) 1.00 (0.96–1.05) 1.01 (0.97–1.05)
Optimism 14.80 (3.68) 1.02 (0.97–1.07) 1.02 (0.97–1.07) 0.99 (0.96–1.03) 1.00 (0.96–1.03)
Continued
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Table 2. (Continued)
Variable
No (%) or
Mean (SD)
Symptom attribution Number of attributed symptoms
Unadjusted OR
(95% CI)
Adjusted ORa
(95% CI)
Unadjusted RR
(95% CI)
Adjusted RRa
(95% CI)
Somatization 4.18 (3.25) 1.04 (0.98–1.09) 1.05 (0.99–1.11) 1.03 (0.99–1.07) 1.02 (0.99–1.07)
Somatosensory
amplification
23.52 (6.16) 1.02 (0.99–1.04) 1.03 (1.00–1.06) 0.99 (0.98–1.01) 0.99 (0.97–1.01)
Symptoms
Number of symptoms
in previous 24 hrs
2.60 (2.70) 1.06 (0.99–1.13) 1.07 (1.00–1.15) 1.05 (1.01–1.10) 1.04 (1.00–1.09)
Severity of symptoms
in previous 24 hrs
2.95 (3.29) 1.04 (0.98–1.09) 1.05 (0.99–1.11) 1.05 (1.01–1.08) 1.04 (1.00–1.08)
Expected likelihood
of symptoms
5.42 (6.03) 1.06 (1.03–1.10) 1.06 (1.02–1.09) 1.03 (1.01–1.05) 1.03 (1.01–1.05)
Medicine-related beliefs
Modern health worries 25.82 (20.37) 1.01 (1.00–1.02) 1.02 (1.01–1.03) 1.01 (1.00–1.01) 1.01 (1.00–1.01)
BMQ overuse 10.91 (3.28) 1.01 (0.96–1.07) 1.03 (0.97–1.09) 1.02 (0.98–1.06) 1.01 (0.98–1.05)
BMQ harm 7.94 (2.68) 1.06 (0.99–1.07) 1.10 (1.02–1.08) 1.01 (0.97–1.05) 1.00 (0.95–1.05)
Perceived sensitivity
to medicines
7.26 (2.81) 1.07 (1.00–1.14) 1.09 (1.02–1.17) 1.01 0.97–1.04) 0.99 (0.96–1.03)
Trust in medicine
development
11.72 (2.10) 0.92 (0.85–1.00) 0.91 (0.83–0.99) 0.96 (0.91–1.01) 0.97 (0.92–1.02)
Trust in pharmaceutical
companies
5.42 (1.63) 0.87 (0.78–0.98) 0.88 (0.79–0.98) 0.92 (0.85–1.00) 0.93 (0.86–1.01)
Notes. Bold = significant at p < .05.
OR = odds ratio; RR = rate ratio; BMQ = belief about medicines questionnaire.
aControlling for gender, age, ethnicity, employment, education and experimental condition.
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wasno effect of the severity of baseline symptoms on the odds of symptomattribution. For
each increase in participants’ likelihoodof expected symptoms, therewas a 6% increase in
the odds of attributing symptoms to the tablet. Both number and severity of previous
symptoms, and expected likelihood of symptoms were associated with the number of
symptoms participants go on to attribute to the tablet. Each one-point increase in these
variables was associatedwith a 4%, 4%, and 3% increase in the rate of symptoms attributed
to the tablet, respectively.
Medicine-related beliefs
Each increase in modern health worries, belief that medicines cause harm and perceived
sensitivity to medicine score was associated with a 2%, 10%, and 9% increase in the odds,
respectively, of participants attributing symptoms to the tablet. For each increase in
participants’ level of trust inmedicine development andpharmaceutical companies, there
was a 9% and 12% decrease in the odds of participants attributing symptoms to the tablet,
respectively. There was no effect of these variables on the number of symptoms
participants go on to attribute to the tablet, apart frommodern health worries, whichwas
associated with a 1% increase in the rate of symptoms attributed to the tablet.
Guess at tablet identity and sensitivity analysis
Only nine of the 203 participants guessed that the tablet was a placebo, and the mean
confidence of participantswho guessed thiswas 2.22 of 5. All other participants identified
it as a form of active medication or simply stated that they did not know what it was. Re-
running the primary analysis without the participants who guessed the tablet was a
placebo did not change any of the adjusted results, see Supporting Information for full
results.
Post hoc analyses
Adjusting for all other variables, being male increased odds of symptom attribution,
OR = 1.92, 95% CI (1.23–2.99), and each 1-year increase in age was associated with a
decrease in the odds of symptom attribution, OR = 0.97, 95% CI (0.94–0.99): All other
predictors for the odds of symptom attribution were non-significant. For the number of
symptoms attributed to the tablet, increases in somatosensory amplification were
associatedwith a decrease in the rate of symptoms attributed to the tablet, RR = 0.97, 95%
CI (0.96–0.99), while expected likelihood of symptoms and modern health worries were
associated with an increase in the rate of symptoms attributed to the tablet, RR = 1.02,
95% CI (1.00–1.04) and RR = 1.01 95% CI (1.00–1.01). No other predictors were
significant.
Discussion
Summary of main results
This study suggests that several factors may predispose people towards experiencing a
nocebo effect after taking a new medication. In terms of demographic predictors, men
were more likely to attribute symptoms to the tablet than women, even after controlling
for all variables measured. This is despite previous findings from a systematic review
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suggesting no robust evidence for an effect of gender on nocebo responses (Webster
et al., 2016). This might have been due to the way that nocebo effects were induced. It
may be that men are specifically susceptible to nocebo effects induced through
information which alters expectancies, something which has been shown previously by
Klosterhalfen et al. (2009). In addition, despite previous evidence showing no effect of
age in predicting nocebo effects (Webster et al., 2016), we found older participants had a
decreased odds of experiencing nocebo effects than younger participants. It is unclear
why this should be so, particularly as the age range was not very large (18–64 years,
SD = 8.63). One reason could be due to the fact that in the previous studies reviewed by
Webster et al. (2016), the age spread of participants studied was different to the age
spread in this study. Interestingly, gender and age did not affect the number of symptoms
participants go on to attribute to the tablet, suggesting they play more of a ‘predisposing’
role rather than affecting the intensity of a nocebo response. Other demographic factors
such as education or employment status showedno effect, supporting the results from the
review (Webster et al., 2016).
In terms of psychological characteristics, there was only an association between
anxiety scores after reading the PIL and the number of attributed symptoms, similar to
previous findings showing a weak effect of anxiety (Webster et al., 2016). The fact that
only anxiety scores after reading the leaflet had an effect on symptom attribution suggests
that the effect of anxiety on nocebo responding is situational. Only anxiety immediately
after thinking about what symptoms to expect had an effect, as opposed to anxiety at the
beginning or end of the study. It is surprising that anxiety levels were only related to the
number of symptoms attributed and not the odds of participants attributing symptoms to
the tablet. It is possible, however, that in this case, the lack of an association with anxiety
and the odds of symptom attribution reflected the generally low levels of state anxiety
seen in this sample, which in turn probably reflected the voluntary nature of the
experiment. Higher levels of anxiety, and a different pattern of results, might be seen
among patients for whom a medication is necessary, rather than voluntary.
More general personality characteristics such as optimism, somatization, and
somatosensory amplification did not show any significant associations supporting the
inconsistent effects seen for these factors in a recent systematic review (Webster et al.,
2016). However, beliefs that directly concerned medication, such as a belief that
medicines cause harm,modern healthworries, perceived sensitivity tomedicines, trust in
medicine development, and trust in pharmaceutical companies were all associated with
the odds of symptom attribution. Attempts to predict and prevent nocebo responses
might therefore be better directed at attitudes related to medicine rather than on more
dispositional factors. It is interesting that these factors (apart frommodern healthworries)
did not affect the number of symptoms attributed. This may be because they do not have
much weight in affecting the intensity of a nocebo response, or it could be because our
sample consisted of healthy individualswho are unlikemost people that takemedications.
This reduces our ability to detect the influence of potential psychological predictors
which may show more variation in less healthy samples.
The fact that participants with more symptoms at baseline were more likely to attribute
symptoms to the tablet, and then go on to attribute a higher number of symptoms to the
tablet adds support to the theory that many nocebo effects could be due tomisattribution of
coincidental symptoms (Faasse & Petrie, 2013; Petrie et al., 2004). This suggestion is
supported by the apparently similar nature of the symptoms reported at baseline and post-
exposure. The more symptoms a participant has at baseline, the more opportunity there is
for oneof these symptoms to bemisattributed as a symptomcaused by the tablet. In addition
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participants with higher expectations of developing side effects from the tablet were more
likely to attribute symptoms to the tablet and then attribute a higher number of symptoms to
the tablet (even after controlling for all other variables), supporting the role that negative
expectations play in generating nocebo effects (Barsky et al., 2002; Hahn, 1997).
Limitations
One limitation inherent in our design was that participants might have engaged in
symptom monitoring more than they would have in daily life after taking a tablet. We
attempted to reduce this by occupying participants with cognitive tasks after taking the
tablet; however, this is still likely to have resulted in raised levels of symptom reporting.
On the other hand, it is also likely that those who volunteered for our study were people
whowere generally trusting ofmedications ormedical science, as shownby the lowmean
scores in baseline anxiety, perceived sensitivity to medicine, and modern health worries,
and high mean scores for trust in medicine development and pharmaceutical companies.
Given that these factorsmay reduce the likelihood of nocebo effects occurring, the rate of
symptom attribution in our study could also be an underrepresentation compared to the
general public.
It is also possible that someof the symptomsparticipants experienced could havebeen
due to natural variation, and were not triggered by the sham pill. Future studies should
address this limitation by including a control group who do not receive a pill. As trust in
medicine and pharmaceutical companies was measured after participants had taken the
pill, readers should also be cautious in interpreting these results.
Other limitations concern the representativeness of our participants who were
particularly well educated, with 65% having a higher education qualification, and young,
with amean age of 27. In addition, participants were only given a relatively short duration
to report any symptoms, it is likely that more symptoms would have been reported if a
longer duration was given. The sample size calculation for this study was based on the
requirements of our linked RCT, rather than the ability to assess associations between
baseline measures and symptom attribution. As such, the results reported here should be
interpreted with caution. This is, however, one of the largest studies to date to have
examined these effects on symptom attribution (Webster et al., 2016).
Finally, in our study, we chose to minimize the amount of deception required by
informing participants that wewould not tell them the identity of the tablet until after the
study was completed, rather than providing them with a false cover story about the
identity of the tablet. This procedure aligns with the principles of authorized deception
(Miller et al., 2005) and, as our results demonstrate, is an effective way of triggering the
nocebo response.One additional positive feature of this procedure is that our resultswere
not influenced by participants’ idiosyncratic preconceived perceptions about the risks
and benefits of any one specific medicine, while symptom expectations were kept
uniform across participants by providing them with a PIL containing the essential details
about their tablet. In real life, of course, participants usually are aware of the medication
they have taken, and the impact of the variables we assessed may not be as clear-cut.
Implications for clinical practice
Although many predictors only showed small effect sizes, given how common nocebo-
induced side effects can be, any way to reduce them may result in a large impact at a
population level. Patients with high expectations of side effects, negative beliefs about
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medicines, low trust in pharmaceutical companies or the way in which medicines are
developed, or high perceived sensitivity to medicines may benefit from reassurance by
clinical practitioners or interventions aimed at correcting any unrealistic beliefs or
expectations they may have about their medication.
Future research
To allow clinicians to identify patients at risk of a nocebo response, it is important for
future research to replicate the investigation of baseline predictors of nocebo responses,
preferably in a patient sample to confirm if the factors found in this study are important in
predicting the attribution of non-specific symptoms to a real medication. This would also
be useful to shed more light on whether there are different factors that affect someone
being a nocebo responder or not in a given situation, or the intensity of a nocebo response.
It is also important for future research to try and establish what the role of gender is in
nocebo effects. Due to the extensive literature on gender differences in symptom
reporting (van Wijk & Kolk, 1997), it has often been assumed that women are more
susceptible to nocebo effects than men. However, a previous review found no evidence
for this, while this trial showedmen to bemore susceptible. Further research is needed to
decipher this relationship.
Conclusions
The results from this study suggest that it is hard to predict who is at risk of
developing nocebo responses to their medicines just from their general demograph-
ics or personality. Instead, the results suggest we should be looking at more specific
factors relating to their beliefs about the supposed exposure. In addition, we should
also take into account the number of symptoms they are experiencing before they
are exposed and their side effect expectations. Future work is needed to investigate
these factors in a patient sample and to decipher the relationship between gender
and nocebo effects.
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